- Home
- WOOF vs SLS Comparison
WOOF vs SLS Comparison
Compare WOOF & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WOOF | SLS |
|---|---|---|
| Founded | 1965 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 871.9M | 706.7M |
| IPO Year | 2020 | 2007 |
Fundamental Metrics
Financial Performance| Metric | WOOF | SLS |
|---|---|---|
| Price | $2.68 | $4.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 1 |
| Target Price | $4.04 | ★ $10.00 |
| AVG Volume (30 Days) | 3.9M | ★ 6.6M |
| Earning Date | 03-11-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 108.11 | 50.00 |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $5,961,467,000.00 | N/A |
| Revenue This Year | $2.73 | N/A |
| Revenue Next Year | $1.60 | $67.40 |
| P/E Ratio | $91.67 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.24 | $0.95 |
| 52 Week High | $4.19 | $6.14 |
Technical Indicators
Market Signals| Indicator | WOOF | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 45.16 | 43.93 |
| Support Level | $2.34 | $3.35 |
| Resistance Level | $3.26 | $5.01 |
| Average True Range (ATR) | 0.21 | 0.49 |
| MACD | -0.04 | -0.12 |
| Stochastic Oscillator | 26.17 | 0.32 |
Price Performance
Historical ComparisonAbout WOOF Petco Health and Wellness Company Inc.
Petco Health and Wellness Co Inc is a pet specialty retailer focused on improving the lives of pets, pet parents, and its own partners with pet care centers in approximately 50 states, the District of Columbia and Puerto Rico. The Company also offers an expanded range of consumables, supplies, and services through its website and mobile app.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.